Browse All

Current Filters

CLEAR FILTER x

TITLE

Pregnancy and Infant Outcomes in Females Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of over 3,000 Pregnancies to Date

Author:Bove, Riley   Pietrasanta, Carlo   Oreja-Guevara, Celia   Hellwig, Kerstin   Dobson, Ruth   Vukusic, Sandra   Lin, Chien-Ju   Goncalves Pereira Alvarez, Daniela   Zecevic, Dusanka   Ferreira, Germano   Craveiro, Licinio   Pasquarelli, Noemi   McElrath, Thomas   

Session Name:S7: Multiple Sclerosis: Special Populations and Non-MS CNS Neuroinflammatory Diseases  

Topic:Multiple Sclerosis  

Program Number:S7.004  

Author Institution:University of California, San Francisco, Berkeley, CA  University of Milan, Milan, Italy  Neurology, Hospital Clínico San Carlos, Madrid, Spain  St. Josef Hospital Bochum, Bochum, Germany  Wolfson Institute of Population Health, Queen Mary University, London, United Kingdom  Hopital Neurologique Pierre Wertheimer, BRON Cedex, France  Roche Products Ltd. , Welwyn Garden City, United Kingdom  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Brigham and Women's Hospital, Boston, MA  

OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis

Author:Newsome, Scott   Krzystanek, Ewa   Selmaj, Krzysztof   Goldstick, Lawrence   Figueiredo, Catarina   Townsend, Ben   Wolf, Christian   Zecevic, Dusanka   Giacobino, Caroline   Bortolami, Oscar   Shen, Yun-An   Kletzl, Heidemarie   Clinch, Susanne   Centonze, Diego   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.006  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  School of Health Sciences in Katowice, Katowice, Poland  Centrum Neurologii, Lodz, Poland  University of Cincinnati, Cincinnati, OH  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Lycalis sprl, Brussels, Belgium  Genentech, San Fransisco, CA  Tor Vergata University, Rome, Italy  

OCARINA I, Phase Ib Study: Dose Selection of Subcutaneous Ocrelizumab in Patients with Multiple Sclerosis

Author:Newsome, Scott   Goldstick, Lawrence   Townsend, Ben   Zecevic, Dusanka   Augustin, Aisha   Figueiredo, Catarina   Clinch, Susanne   Giacobino, Caroline   Bortolami, Oscar   Shen, Yun-An   Kletzl, Heidemarie   Bermel, Robert   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.003  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  University of Cincinnati, Cincinnati, OH  F. Hoffmann-La Roche Ltd., Basel, Switzerland  Roche Products Ltd. , Welwyn, United Kingdom  Genentech, San Fransisco, CA  Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH